Browsing Tag
Indianapolis
17 posts
Corteva and Globachem form 50-50 crop protection JV ahead of Vylor separation
Corteva and Globachem have agreed a 50-50 crop protection joint venture focused on late-pipeline and commercial-stage products, adding another growth platform to New Corteva only weeks before Vylor is scheduled to separate.
Eli Lilly targets autoimmune pipeline with $2.875bn Merida Biosciences acquisition
Eli Lilly is paying up to $2.875 billion for privately held Merida Biosciences only about 17 months after the biotech launched with $121 million. The lead asset remains in Phase 1, making the transaction less a conventional pipeline purchase than a bet that selectively eliminating disease-causing antibodies can open a new class of autoimmune and allergy medicines.
Why Morales Beverage Group wants RNDC Indiana while the wider distributor is in Chapter 11
MBG targets RNDC Indiana as beverage distribution reshuffles after Chapter 11, but court approval and supplier continuity remain the decisive hurdles.
Indiana’s worst flooding in decades leaves more than 1,000 displaced and triggers federal emergency response
Historic Indiana flooding kills seven and displaces more than 1,000 as record White River levels leave communities facing a major recovery.
Indiana flooding kills six as White River breaks century-old records and hundreds flee homes
At least six people have died as historic flooding spreads across Indiana after days of severe Midwest storms, forcing hundreds from their homes, triggering water rescues and pushing sections of the White River beyond records dating to 1913.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Why Lilly’s $3.25bn Kelonia acquisition signals a manufacturing shift across the entire CAR-T landscape
Eli Lilly agrees to acquire Kelonia Therapeutics for up to $7B. What the iGPS in vivo CAR-T platform means for oncology and LLY investors. Read the analysis.
How Mark Sanchez went from stabbing victim to suspect in an Indianapolis confrontation
Former NFL quarterback Mark Sanchez was stabbed and later arrested in Indianapolis. Learn what happened, what charges he faces, and how it could affect his Fox Sports career.
Inside the Indianapolis mass shooting: how two people lost their lives and five others were injured
Seven people were shot in Indianapolis, leaving two dead. Police are still searching for suspects. Find out how the city is responding to the tragedy.